Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-01023-z
Abstract: Purpose Axitinib is an orally active multikinase inhibitor currently used to treat patients with metastatic renal cell carcinoma (RCC). This study examined the pharmacokinetics of axitinib and the relationship between peak drug concentration (C max… read more here.
Keywords: renal cell; orally active; cell carcinoma; metastatic renal ... See more keywords
Abstract 2873: Imaging tumor heterogeneity after multikinase inhibitor therapy in rat hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-2873
Abstract: Purpose To assess tumor tissue perfusion and vascular permeability through multiparametric functional imaging, and to evaluate their correspondence with histopathologic parameters of necrosis and hypoxia in a rat model of hepatocellular carcinoma treated with a… read more here.
Keywords: hepatocellular carcinoma; heterogeneity; multikinase inhibitor; tumor heterogeneity ... See more keywords
Timing of multikinase inhibitor initiation in differentiated thyroid cancer
Sign Up to like & getrecommendations! Published in 2017 at "Endocrine-Related Cancer"
DOI: 10.1530/erc-17-0016
Abstract: There are limited treatment options for patients with radioactive iodine refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load… read more here.
Keywords: multikinase; differentiated thyroid; thyroid cancer; cancer ... See more keywords
Rare complications of multikinase inhibitor treatment.
Sign Up to like & getrecommendations! Published in 2018 at "Archives of endocrinology and metabolism"
DOI: 10.20945/2359-3997000000090
Abstract: OBJECTIVE The advent of multikinase inhibitor (MKI) therapy has led to a radical change in the treatment of patients with advanced thyroid carcinoma. The aim of this manuscript is to communicate rare adverse events that… read more here.
Keywords: endocrinology; line treatment; treatment; multikinase inhibitor ... See more keywords